RESUMEN
Evidence suggests that circadian rhythms are regulated through diffusible signals generated by the suprachiasmatic nucleus (SCN). Vasoactive intestinal peptide (VIP) is located in SCN neurons positioned to receive photic input from the retinohypothalamic tract and transmit information to other SCN cells and adjacent hypothalamic areas. Studies using knockout mice indicate that VIP is essential for synchrony among SCN cells and for the expression of normal circadian rhythms. To test the hypothesis that VIP is also an SCN output signal, we recorded wheel-running activity rhythms in hamsters and continuously infused the VIP receptor agonist BAY 55-9837 in the third ventricle for 28 days. Unlike other candidate output signals, infusion of BAY 55-9837 did not affect activity levels. Instead, BAY 55-9837 lengthened the circadian period by 0.69 +/- 0.04 h (P < 0.0002 compared with controls). Period returned to baseline after infusions. We analyzed the effect of BAY 55-9837 on cultured SCN from PER2::LUC mice to determine if lengthening of the period by BAY 55-9837 is a direct effect on the SCN. Application of 10 muM BAY 55-9837 to SCN in culture lengthened the period of PER2 luciferase expression (24.73 +/- 0.24 h) compared with control SCN (23.57 +/- 0.26, P = 0.01). In addition, rhythm amplitude was significantly increased, consistent with increased synchronization of SCN neurons. The effect of BAY 55-9837 in vivo on period is similar to the effect of constant light. The present results suggest that VIP-VPAC2 signaling in the SCN may play two roles, synchronizing SCN neurons and setting the period of the SCN as a whole.
Asunto(s)
Ritmo Circadiano/fisiología , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Péptido Intestinal Vasoactivo/metabolismo , Animales , Ritmo Circadiano/efectos de los fármacos , Cricetinae , Hipotálamo/metabolismo , Luz , Masculino , Mesocricetus , Ratones , Ratones Noqueados/metabolismo , Actividad Motora , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/fisiología , Fragmentos de Péptidos , Receptores de Péptido Intestinal Vasoactivo/fisiología , Transducción de Señal/fisiología , Núcleo Supraquiasmático/metabolismo , Núcleo Supraquiasmático/fisiología , Péptido Intestinal Vasoactivo/farmacologíaRESUMEN
In the developing hypothalamus, a variety of neurons are generated adjacent to each other in a highly coordinated, but poorly understood process. A critical question that remains unanswered is how coordinated development of multiple neuronal types is achieved in this relatively narrow anatomical region. We focus on dopaminergic (DA) and oxytocinergic (OT) neurons as a paradigm for development of two prominent hypothalamic cell types. We report that the development of DA and OT-like neurons in the zebrafish is orchestrated by two novel pathways that regulate the expression of the homeodomain-containing protein Orthopedia (Otp), a key determinant of hypothalamic neural differentiation. Genetic analysis showed that the G-protein-coupled receptor PAC1 and the zinc finger-containing transcription factor Fezl act upstream to Otp. In vivo and in vitro experiments demonstrated that Fezl and PAC1 regulate Otp at the transcriptional and the post-transcriptional levels, respectively. Our data reveal a new genetic network controlling the specification of hypothalamic neurons in vertebrates, and places Otp as a critical determinant underlying Fezl- and PAC1-mediated differentiation.
Asunto(s)
Proteínas de Homeodominio/genética , Hipotálamo/embriología , Factores de Transcripción/genética , Proteínas de Pez Cebra/genética , Pez Cebra/embriología , Pez Cebra/genética , Animales , Secuencia de Bases , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Cartilla de ADN/genética , Dopamina/metabolismo , Regulación del Desarrollo de la Expresión Génica , Proteínas de Homeodominio/metabolismo , Hipotálamo/citología , Hipotálamo/metabolismo , Modelos Neurológicos , Mutación , Neuronas/metabolismo , Oligodesoxirribonucleótidos Antisentido/genética , Oxitocina/metabolismo , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/genética , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/metabolismo , Receptores de Péptido Intestinal Vasoactivo/genética , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Transducción de Señal , Factores de Transcripción/metabolismo , Pez Cebra/metabolismo , Proteínas de Pez Cebra/metabolismoRESUMEN
BACKGROUND & AIMS: Crohn's disease (CD) is a chronic debilitating disease of unknown etiology that is characterized by severe inflammation of the colon. Vasoactive intestinal peptide (VIP) has recently emerged as a promising candidate for treatment of inflammatory Th1-driven diseases. We studied the effect of VIP in trinitrobenzene sulfonic acid (TNBS)-induced colitis, which has clinical and molecular features in common with CD. METHODS: A 3-mg enema of TNBS was given to BALB/c mice, and VIP (1 nmol) was given either as a single dose at 12 hours or every other day. Weight loss, histopathology, and chemokine and cytokine levels in serum and colon extracts were assessed. VIP was also tested given 5 days after the onset of TNBS-induced colitis, and its effect was analyzed given a second dose of TNBS. RESULTS: Treatment with VIP reduced the clinical and histopathologic severity of TNBS-induced colitis, abrogating body weight loss, diarrhea, and macroscopic and microscopic intestinal inflammation. The therapeutic effects of VIP were associated with down-regulation of both inflammatory and Th1-driven autoimmune responses, including tumor necrosis factor alpha, interleukin 1, and interleukin 6 in colon extracts and serum as well as interferon gamma by splenic and lamina propria CD4(+) T cells. VIP reduced disease severity when given after disease onset and dramatically reduced disease recurrence given a second dose of TNBS. CONCLUSIONS: Our data suggest that VIP has beneficial prophylactic and therapeutic effects in TNBS-induced colitis and is a promising candidate to test for potential benefits in CD.
Asunto(s)
Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/farmacología , Péptido Intestinal Vasoactivo/farmacología , Animales , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Colitis/inmunología , Enfermedad de Crohn/inducido químicamente , Enfermedad de Crohn/inmunología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Regulación hacia Abajo/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Receptores de Tipo I del Polipéptido Intestinal Vasoactivo , Células TH1/metabolismo , Células Th2/metabolismo , Ácido Trinitrobencenosulfónico , Síndrome Debilitante/inducido químicamente , Síndrome Debilitante/tratamiento farmacológico , Síndrome Debilitante/inmunologíaRESUMEN
Pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) activate two shared receptors, VPAC1 and VPAC2. Activation of VPAC1 has been implicated in elevating glucose output, whereas activation of VPAC2 may be involved in insulin secretion. A hypothesis that a VPAC2-selective agonist would enhance glucose disposal by stimulating insulin secretion without causing increased hepatic glucose production was tested using a novel selective agonist of VPAC2. This agonist, BAY 55-9837, was generated through site-directed mutagenesis based on sequence alignments of PACAP, VIP, and related analogs. The peptide bound to VPAC2 with a dissociation constant (K(d)) of 0.65 nmol/l and displayed >100-fold selectivity over VPAC1. BAY 55-9837 stimulated glucose-dependent insulin secretion in isolated rat and human pancreatic islets, increased insulin synthesis in purified rat islets, and caused a dose-dependent increase in plasma insulin levels in fasted rats, with a half-maximal stimulatory concentration of 3 pmol/kg. Continuous intravenous or subcutaneous infusion of the peptide reduced the glucose area under the curve following an intraperitoneal glucose tolerance test. The peptide had effects on intestinal water retention and mean arterial blood pressure in rats, but only at much higher doses. BAY 55-9837 may be a useful therapy for the treatment of type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Fragmentos de Péptidos/farmacología , Receptores de Péptido Intestinal Vasoactivo/agonistas , Péptido Intestinal Vasoactivo/farmacología , Secuencia de Aminoácidos , Animales , Presión Sanguínea/efectos de los fármacos , Células Cultivadas , Diarrea/tratamiento farmacológico , Diarrea/metabolismo , Glucosa/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Hormonas/sangre , Humanos , Inyecciones Intravenosas , Inyecciones Subcutáneas , Secreción de Insulina , Islotes Pancreáticos/efectos de los fármacos , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Ratas , Ratas Wistar , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria , Receptores de la Hormona Hipofisaria/metabolismo , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Receptores de Tipo II del Péptido Intestinal Vasoactivo , Receptores de Tipo I del Polipéptido Intestinal Vasoactivo , Péptido Intestinal Vasoactivo/análogos & derivados , Péptido Intestinal Vasoactivo/química , Péptido Intestinal Vasoactivo/metabolismoRESUMEN
To elucidate the functional role of the second extracellular loop of human vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide (VIP/PACAP) receptor (hVPAC1R), surface expression, ligand binding, and receptor activation were analyzed. Amino acids in the entire second extracellular loop were individually substituted by alanine by site-directed mutagenesis. The mutant and wild-type receptors were transiently expressed in HEK293 cells and purified cell membranes were tested for the ability to bind VIP, while the receptor activity was measured as potency of cAMP production analysed on intact cells. Surface expression of the substituted conserved residues, W286A, I289A, W294A, and W295A, was evidently decreased to 20-30% compared to the wild-type expression. W286A also showed an significantly reduced potency of cAMP production. Substituted residues as F280A, E281A, and G284A showed a significant reduction in the potency of stimulated cAMP production amounting to 8-46-fold, compared to the wild-type with unaffected surface expression and VIP binding. These results indicate that some residues in the second extracellular loop of the human VPAC1R participate in the active mechanism of a ligand-mediated response without being directly involved in the binding of VIP.
Asunto(s)
Receptores de la Hormona Hipofisaria/química , Receptores de la Hormona Hipofisaria/metabolismo , Receptores de Péptido Intestinal Vasoactivo/química , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Sitios de Unión/fisiología , Células Cultivadas , AMP Cíclico/metabolismo , ADN Complementario , Humanos , Radioisótopos de Yodo , Riñón/citología , Ligandos , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Estructura Terciaria de Proteína , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria , Receptores de la Hormona Hipofisaria/genética , Receptores de Péptido Intestinal Vasoactivo/genética , Receptores de Tipo I del Polipéptido Intestinal Vasoactivo , Homología de Secuencia de Aminoácido , Transfección , Péptido Intestinal Vasoactivo/metabolismo , Péptido Intestinal Vasoactivo/farmacologíaRESUMEN
Melatonin secretion from the mammalian pineal gland is strongly stimulated by noradrenaline and also by vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). Three types of receptors for VIP and PACAP have been characterized so far: VIP1/PACAP receptors and VIP2/PACAP receptors, which possess similar high affinities for VIP and PACAP, and PACAP1 receptors which exhibit a 100-1000-fold higher affinity for PACAP. The aim of the present study was to characterize the receptor subtype(s) mediating the stimulatory effects of VIP and PACAP on melatonin synthesis in the rat pineal gland. Autoradiographic studies showed that PACAP and VIP were equally potent in displacing binding of radioiodinated PACAP27 from pineal sections. Amplification of pineal complementary DNAs by polymerase chain reaction using specific primers for the different receptor subtypes revealed that all three receptor messenger RNAs are expressed and that VIP1/PACAP receptor messenger RNA was predominant over VIP2/PACAP receptor messenger RNA. In vitro, VIP and PACAP stimulated melatonin synthesis with similar high potency and the effect of the two peptides were not additive. The selective VIP1/PACAP receptor agonists [R16]chicken secretin (1-25) and [K15, R16, L27]VIP(1-7)/growth hormone releasing factor(8-27) were significantly more potent than the selective VIP2/PACAP receptor agonist RO 25-1553 in stimulating melatonin secretion. The stimulatory effects of VIP and PACAP were similarly inhibited by the VIP1/PACAP antagonist [acetyl-His1, D-Phe2, K15, R16, L27]VIP(3-7)/growth hormone releasing factor(8-27). These data strongly suggest that VIP and PACAP exert a stimulatory effect on melatonin synthesis mainly through activation of a pineal VIP1/PACAP receptor subtype.
Asunto(s)
Adenilil Ciclasas/metabolismo , Glándula Pineal/química , Glándula Pineal/enzimología , Receptores de la Hormona Hipofisaria/análisis , Receptores de Péptido Intestinal Vasoactivo/análisis , Agonistas Adrenérgicos beta/farmacología , Animales , Autorradiografía , Broncodilatadores/farmacología , Activación Enzimática/efectos de los fármacos , Expresión Génica/fisiología , Radioisótopos de Yodo , Isoproterenol/farmacología , Masculino , Melatonina/metabolismo , Neuropéptidos/farmacología , Neurotransmisores/farmacología , Fragmentos de Péptidos/farmacología , Péptidos Cíclicos/farmacología , Polipéptido Hipofisario Activador de la Adenilato-Ciclasa , ARN Mensajero/análisis , Ratas , Ratas Wistar , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria , Receptores de la Hormona Hipofisaria/genética , Receptores de la Hormona Hipofisaria/metabolismo , Receptores de Péptido Intestinal Vasoactivo/genética , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Péptido Intestinal Vasoactivo/análogos & derivados , Péptido Intestinal Vasoactivo/farmacologíaRESUMEN
VIP receptor binding in the frontal cortex, a region with substantial neuronal loss, was unaltered in individuals who had died of acquired immunodeficiency syndrome (AIDS) neurotoxicity. In contrast, ascorbic acid, which suppresses human immunodeficiency virus (HIV) replication and modulates glutamatergic neuronal activity, was reduced by nearly 60% in the same brain region. These findings indicate that while neurons containing ascorbic acid may be lost, vasoactive intestinal polypeptide (VIP) receptor bearing cells remain viable. This finding supports previous observations that VIP prevents HIV induced neuronal death. The reduced ascorbic acid levels may contribute to particular neurons being vulnerable to damage from oxidative stress and possibly clinically to the development of dementia.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/metabolismo , Ácido Ascórbico/metabolismo , Lóbulo Frontal/metabolismo , Lóbulo Frontal/virología , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Adulto , Anciano , Química Encefálica/fisiología , Niño , Femenino , Lóbulo Frontal/química , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Cisteína , Receptores de Péptido Intestinal Vasoactivo/química , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Péptido Intestinal Vasoactivo/metabolismo , Secuencia de Aminoácidos , Animales , Células COS , AMP Cíclico/metabolismo , ADN Complementario , Humanos , Cinética , Modelos Estructurales , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Mutación Puntual , Estructura Secundaria de Proteína , Receptores de Tipo I del Polipéptido Intestinal Vasoactivo , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Transfección , Péptido Intestinal Vasoactivo/farmacologíaRESUMEN
Vasoactive intestinal peptide (VIP)1 receptors in rats and humans recognize peptide histidine isoleucineamide (PHI) with high and low affinity, respectively. We took advantage of this phenotypic difference to identify the domain responsible for the selective recognition of PHI by rat and human receptors which display >80% sequence identity. After transfection of human and rat receptors in COS cells, the ratio of IC50 for PHI/IC50 for VIP (referred to as P/V) in inhibiting 125I-VIP binding was shown to be >1,000 and <40, respectively. Construction of eight rat/human receptor chimerae by overlap polymerase chain reaction and determination of their P/V ratios demonstrated that the critical domain for PHI recognition is present within a sequence comprising part of the first extracellular loop and third transmembrane domain. This domain contains three different amino acids numbered according to human and rat sequences, respectively, e.g. Gln207 (human) versus His208 (rat), Gly211 versus Ala212 and Met219 versus Val220. Site-directed mutagenesis introducing individual, double, or triple mutations in a chimeric construct revealed that all three amino acids were involved in the recognition of PHI. Triple mutations were then introduced in the wild-type receptors i.e. Q207H, G211A, M219V human VIP1 receptor and H208Q, A212G, V220M rat VIP1 receptor, resulting in a complete change in their phenotype from human to rat and from rat to human, respectively. The results demonstrate that three nonadjacent amino acids are responsible for the selective recognition of PHI by human and rat VIP1 receptors.
Asunto(s)
Péptido PHI/metabolismo , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Secuencia de Aminoácidos , Animales , Línea Celular , ADN Complementario , Humanos , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Fenotipo , Ratas , Receptores de Péptido Intestinal Vasoactivo/genética , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Homología de Secuencia de Aminoácido , Especificidad de la EspecieRESUMEN
Radioligand assays of the membrane fraction of hen hypothalamic tissues involving the preoptic (HPOA) or median eminence (HMEA) areas revealed the presence of a specific binding component to chicken vasoactive intestinal peptide (cVIP) having properties of a receptor. The equilibrium dissociation constant (Kd) was 0.70 +/- 0.07 nM (Mean +/- SEM; N = 5) in HPOA and 1.02 +/- 0.15 nM (N = 5) in HMEA as estimated by Scatchard analysis of saturation studies, and was 0.91 +/- 0.11 nM (N = 3) (HPOA) and 1.25 +/- 0.09 nM (N = 3) (HMEA) as determined by a kinetic analysis. The maximum binding capacity (Bmax) obtained by Scatchard analysis was 167 +/- 19 fmol/mg protein (N = 5) (HPOA) and 133 +/- 17 fmol/mg protein (N = 5) (HMEA). The Kd and Bmax values obtained by Scatchard analysis were similar in the two areas of the hypothalamus and in both laying and nonlaying hens. Administration of cVIP in vivo caused a decrease in specific cVIP binding. These results suggest the presence of a VIP receptor in the hen hypothalamus.
Asunto(s)
Pollos/metabolismo , Hipotálamo/metabolismo , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Animales , Membrana Celular/metabolismo , Femenino , Radioisótopos de Yodo , Cinética , Eminencia Media/metabolismo , Área Preóptica/metabolismo , Ensayo de Unión Radioligante , Péptido Intestinal Vasoactivo/metabolismoRESUMEN
Using a quantitative in vitro autoradiographic approach, vasoactive intestinal polypeptide (VIP) binding site densities were compared in the post-mortem hypothalamus of human neonate/infant and adult. The densities were similar during development in most of the hypothalamic nuclei and areas examined underlying the stability of 125I-VIP binding sites in the post-mortem hypothalamus of young and adult individuals. However, the ventral part of the medial preoptic area, the medial, lateral, and supramammillary nuclei were characterized by an increase of 125I-VIP binding with age. In young and adult individuals, the highest densities of hypothalamic 125I-VIP binding sites were detected in the supraoptic and infundibular nuclei; the ependyma; the organum vasculosum of the lamina terminalis; the horizontal limb of the diagonal band of Broca; the ventral part of the medial preoptic area (in adult); the suprachiasmatic, paraventricular, and periventricular nuclei; and the medial and lateral mammillary nuclei in adult. Moderate densities were found in the vertical limb of the diagonal band of Broca, the bed nucleus of the stria terminalis, the ventral part of the medial preoptic area in neonate/infant, the medial and lateral mammillary nuclei in neonate/infant, the supramammillary nucleus in adult, the dorsal hypothalamic area, and the ventromedial nucleus. Low to moderate binding site densities were observed in the other hypothalamic regions of young or adult individuals. The nonspecific binding ranged from 15% of the total binding in the anterior hypothalamus to 20% in the mediobasal and posterior hypothalamic levels. Taken together, these results provide evidence for a large distribution of VIP binding sites in neonate/infant and adult human hypothalamus suggesting the implication of VIP in the development of this brain structure and the maintenance of its various functions.
Asunto(s)
Hipotálamo/crecimiento & desarrollo , Hipotálamo/metabolismo , Receptores de Péptido Intestinal Vasoactivo/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Hipotálamo/anatomía & histología , Hipotálamo Anterior/anatomía & histología , Hipotálamo Anterior/crecimiento & desarrollo , Hipotálamo Anterior/metabolismo , Hipotálamo Medio/anatomía & histología , Hipotálamo Medio/crecimiento & desarrollo , Hipotálamo Medio/metabolismo , Hipotálamo Posterior/anatomía & histología , Hipotálamo Posterior/crecimiento & desarrollo , Hipotálamo Posterior/metabolismo , Lactante , Recién Nacido , Radioisótopos de Yodo , Masculino , Persona de Mediana EdadRESUMEN
Vasoactive intestinal peptide (VIP) neurons are present in the suprachiasmatic nucleus (SCN) and project to various hypothalamic nuclei. Several results suggest that hypothalamic VIP is involved in the mediation of synchronizing information. [125I]Vasoactive intestinal peptide binding has been reported to be especially high in the hypothalamus. We show here by radioautography by dipping that [125I]VIP binding is high and homogeneously distributed in the SCN. The correspondence between VIP binding and terminals densities supports the hypothesis that VIP acts through synapses in the SCN. Moderate and fairly homogeneous VIP binding is also found in the paraventricular nucleus (PaVN), whereas VIP terminals are reported to be restricted to the sub-paraventricular area. This suggests that VIP could diffuse and thus function as a paracrine neuromodulator in the PaVN. [125I]Vasoactive intestinal peptide binding is stable along the nycthemer in the suprachiasmatic, peri-, and paraventricular nuclei as well as in all other areas investigated.